Thanks to their low toxicity and high specificity, therapeutic antibodies have enjoyed incredible market success across a range of disease categories. The global antibody discovery market, valued at $11.15 billion in 2025, is expected to surge to $35.35 billion by 2035.
Experts predict this growth will be fuelled by advancements in engineering technologies, automation, and artificial intelligence (AI), which will further streamline antibody identification and optimisation, significantly shorten development timelines and improve cost efficiency.
Multiplexed single-cell analysis is one technology driving this growth. By combining picodroplet microfluidics, multiparameter fluorescence detection and automated cell isolation, these platforms enable scientists to examine secretion, cell identity, viability and functional capability while screening, rather than across disconnected downstream assays.
Download this exclusive eBook from Fluidic Sciences to learn more about:
-
How the global antibody discovery market could evolve in the next 10 years
-
How new technologies are improving efficiency and downstream success rates in antibody discovery
-
Multiplexed rapid B cell screening and the future of antibody discovery
